← Back to Clinical Trials
Recruiting NCT04349852

NCT04349852 Verbal Working Memory and Attention Remediation for Adults With Traumatic Brain Injury.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04349852
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Traumatic Brain Injury
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2021-08-01
Primary Completion 2027-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
BrainHQ Cognitive Training ModulesBrainHQ People Skills Modules

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2021-08-01 with a primary completion date of 2027-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project will examine if computerized cognitive remediation will improve working memory and attention in 25 adults with a mild, moderate, or severe brain injury and compare their cognitive performance to the control group of 25 adults with a mild, moderate, or severe brain injury. The control group will train on computerized Brain Games. Participants in both groups will be assessed prior to training and immediately post-training and one month-post training.

Eligibility Criteria

Inclusion Criteria: * Medically documented mild, moderate, or severe TBI; * All subjects will be older than 18 years of age; * Free from schizophrenia or bipolar disorder, due to the potential influence of such disorders on cognitive functioning; * Free of current alcohol or drug abuse; * At least 12 months post-injury. Exclusion Criteria: * Younger than 18 years old. * A brain injury that is not medically documented. * Being diagnosed with schizophrenia or bipolar disorder. * Current alcohol or drug use diagnosis * Less than 3 months post-injury

Contact & Investigator

Central Contact

Gerald Voelbel, PhD

✉ gv23@nyu.edu

📞 212-998-5827

Principal Investigator

Gerald Voelbel, PhD

PRINCIPAL INVESTIGATOR

NYU Langone Health

Frequently Asked Questions

Who can join the NCT04349852 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04349852 currently recruiting?

Yes, NCT04349852 is actively recruiting participants. Contact the research team at gv23@nyu.edu for enrollment information.

Where is the NCT04349852 trial being conducted?

This trial is being conducted at New York, United States.

Who is sponsoring the NCT04349852 clinical trial?

NCT04349852 is sponsored by NYU Langone Health. The principal investigator is Gerald Voelbel, PhD at NYU Langone Health. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology